#Canada #Vancouver #Immunotherapy #Debentures #BioVaxys

BioVaxys Technology Corp. Converts Debentures

BioVaxys Technology Corp., a clinical-stage biopharmaceutical company based in Vancouver, has recently made headlines with its announcement regarding the conversion of unsecured convertible debentures. This significant financial maneuver reflects the ongoing commitment of BioVaxys to enhance shareholder value and advance its innovative immunotherapy solutions.

On September 15, 2025, BioVaxys issued debentures worth a total of $335,670, allowing holders the option to convert their investment into common shares at their discretion. The conversion announcement has been triggered by several debenture holders, who have opted to convert $160,670 of the principal amount, along with the accrued interest. This results in a total payout of $162,210.67, which primarily consists of the principal and interest owed to the investors.

To fulfill this obligation, BioVaxys has disclosed plans to issue approximately 954,179 shares at a conversion price of $0.17 per share. This development not only signifies a strategic move to manage financial obligations but also demonstrates the confidence of investors in BioVaxys’s robust pipeline of immunotherapeutic products.

Financial Insights

The debentures in question carry an annual interest rate of 10%, indicating a comparatively attractive investment vehicle for shareholders looking for returns linked to the company’s performance in the healthcare sector. The strategic issuance of shares is aligned with the policies set forth by the Canadian Securities Exchange (CSE), signaling that BioVaxys is adhering to proper regulatory frameworks.

Importantly, the issuance of these shares is contingent upon receiving necessary regulatory approvals, particularly from the CSE, which ensures compliance with stock exchange requirements and fosters investor trust.

About BioVaxys

Founded on the principles of innovation in therapeutic development, BioVaxys Technology Corp. focuses on groundbreaking immunotherapies, particularly aimed at treating cancers, infectious diseases, and food allergies. Utilizing their proprietary DPX™ immune-educating technology platform, BioVaxys strives to activate and enhance immune responses against various health threats.

Among their notable product candidates, the company is advancing its lead therapy, maveropepimut-S (MVP-S), which is currently in Phase IIB clinical trials targeting advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer. MVP-S has demonstrated a sound safety profile and encouraging clinical benefits, which bode well for both patient outcomes and investor confidence.

In addition, BioVaxys is exploring innovative solutions such as DPX™+SurMAGE, a dual-targeted immunotherapy platform that combines antigenic peptides to elicit comprehensive immune responses. Other initiatives include developing targeted therapies aimed at food allergies and personalized cancer vaccines, showcasing the company’s diverse approach to tackling serious health issues.

Conclusion

With the conversion of debentures into shares, BioVaxys Technology Corp. embarks on a path designed to empower both its financial health and its mission to revolutionize patient care through innovative immunotherapies. The confidence shown by debenture holders reinforces their commitment to the organization’s long-term vision, paving the way for ongoing advancements in biopharmaceuticals. Investors and healthcare stakeholders alike are encouraged to monitor BioVaxys’s progress as it continues to evolve within the competitive landscape of immunotherapy and biotech solutions.